Diagnostics

Craif Is Taking Home-Market Proof to the Hardest Market

Craif has raised roughly $33 million to expand its urine-based cancer-detection business in the United States. The funding headline matters, but the more useful signal is where the company starts from: Craif says its miSignal test is already offered through more than 2,500 medical institutions and 4,500 pharmacies in Japan, with more than 110,000 tests performed. Its Series D announcement frames the round as an American expansion, not an attempt to create its first real market.